CYB003

CYB003
Clinical data
Other namesCYB-003; deuterated psilocybin analogue; deuterated psilocin analogue
Routes of
administration		By mouth[1]
Drug classSerotonergic psychedelic[1][2]
ATC code
  • None
Pharmacokinetic data
Onset of action30 minutes (Cmax)
Elimination half-life45 minutes

CYB003, or CYB-003, also known as deuterated psilocybin analogue, is a serotonergic psychedelic related to psilocybin which is under development for the treatment of major depressive disorder, alcoholism, and other psychiatric disorders.[1][3][4][5][6][2][7] It is taken by mouth.[1]

It is a tryptamine derivative and is a deuterated analogue of psilocybin and psilocin.[1][4][5][2] The pharmacodynamic profile of CYB003, including its interactions with serotonin receptors and its effects in animals, is similar to that of psilocin.[2] As with psilocin, CYB003 is a potent agonist of the serotonin 5-HT2A receptor and produces psychedelic-like effects in animals.[2] However, it was developed to have improved pharmacokinetic properties compared to psilocybin, including reduced variability in circulating levels, a faster onset of action, and a shorter duration.[7]

As of October 2024, CYB003 is in phase 3 clinical trials for major depressive disorder and is in the preclinical stage of development for alcoholism and other psychiatric disorders.[1][3] Two phase 3 clinical trials for major depressive disorder are being initiated in November 2024 and February 2025.[1][3] The drug is under development by Cybin.[1][3] The chemical structure of CYB003 has not yet been disclosed.[5][4] However, Cybin patented deuterated tryptamines including the dideuterated psilocin analogue PI-α,α-d2 (psilocin dideuterated at the α carbon) in 2023.[8] Other related drugs include the deuterated tryptamine CYB004 and the deuterated phenethylamines CYB005 and CYB210010.[4][9]

  1. ^ a b c d e f g h "CYB 003". AdisInsight. 4 October 2024. Retrieved 23 October 2024.
  2. ^ a b c d e Palfreyman M, Krakowsky J, Morgan M, Canal C, Pathare P, Avery K, et al. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P361. In Vitro and In Vivo Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 47 (Suppl 1): 220–370 (271). doi:10.1038/s41386-022-01485-0. PMC 9714399. PMID 36456694.
  3. ^ a b c d "Delving into the Latest Updates on CYB-003 with Synapse". Synapse. 12 October 2024. Retrieved 23 October 2024.
  4. ^ a b c d Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, et al. (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24): 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419.
  5. ^ a b c Di Martino RM, Maxwell BD, Pirali T (July 2023). "Deuterium in drug discovery: progress, opportunities and challenges". Nat Rev Drug Discov. 22 (7): 562–584. doi:10.1038/s41573-023-00703-8. PMC 10241557. PMID 37277503.
  6. ^ Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST (December 2023). "Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders". Drug Discov Today. 28 (12): 103818. doi:10.1016/j.drudis.2023.103818. PMID 37925136.
  7. ^ a b Inamdar A, Morgan M, Krakowsky J, Reichelt A, Canal C, Mueller T, et al. (December 2022). "ACNP 61st Annual Meeting: Poster Abstracts P271-P540: P362. Pharmacokinetic Profile of CYB003: A Novel, Deuterated Psilocybin Analog for the Potential Treatment of Major Depressive Disorder" (PDF). Neuropsychopharmacology. 47 (Suppl 1): 220–370 (271–272). doi:10.1038/s41386-022-01485-0. PMC 9714399. PMID 36456694.
  8. ^ "Deuterated tryptamine derivatives and methods of use". Google Patents. 17 July 2023. Retrieved 23 October 2024. Binding affinity (Ki) and functional potency (EC50) values of PI and PI-α-d2 are summarized in Table 1. Deuteration was found to have little effect on the affinity and function at key receptor targets. [...] TABLE 1: PI and PI-α,α-d2 Affinities and Functions at Target Serotonin Receptors [...]
  9. ^ Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.